ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
125.667,83
0,85%
S&P 500
6.032,38
0,56%
US Dollar vs BRL
5,97435
0,00%
Bitcoin
96.397,66
-1,12%
Brent Oil
71,98
-0,08%
Registration Strip Icon for default Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Alexion Pharmaceuticals Inc (ALXN)

  7. Alexion Pharmaceuticals Inc (ALXN) Notícias

ALXN

Alexion Pharmaceuticals (ALXN)

Alexion Pharmaceuticals Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:ALXN
DataHoraFonteTítuloCódigoCompanhia
28/07/202305:54KR Market News알렉시온, 화이자 유전자 치료제를 10억 달러 인수 합의NASDAQ:ALXNAlexion Pharmaceuticals Inc
28/07/202305:23KR Market News아스트라제네카, 항암제 수요로 2분기 결과 예상치 상회NASDAQ:ALXNAlexion Pharmaceuticals Inc
26/07/202107:02Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:ALXNAlexion Pharmaceuticals Inc
23/07/202117:55Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ALXNAlexion Pharmaceuticals Inc
22/07/202110:09Edgar (US Regulatory)Post-effective Amendment to an S-8 Filing (s-8 Pos)NASDAQ:ALXNAlexion Pharmaceuticals Inc
22/07/202107:27Edgar (US Regulatory)Post-effective Amendment to Registration Statement (pos Am)NASDAQ:ALXNAlexion Pharmaceuticals Inc
21/07/202110:12Edgar (US Regulatory)Notification Filed by National Security Exchange to Report the Removal From Listing and Registration of Matured, Redeemed or Retired Securities Initial Filing Amendments (25-nse)NASDAQ:ALXNAlexion Pharmaceuticals Inc
15/07/202120:01PR Newswire (US)Moderna Set to Join S&P 500NASDAQ:ALXNAlexion Pharmaceuticals Inc
15/07/202117:05Business WireAlexion Announces Positive Topline Results from Phase 3 Study of ULTOMIRIS® (ravulizumab-cwvz) in Adults with Generalized My...NASDAQ:ALXNAlexion Pharmaceuticals Inc
14/07/202121:00GlobeNewswire Inc.Honeywell International Inc. to Join the NASDAQ-100 Index Beginning July 21, 2021NASDAQ:ALXNAlexion Pharmaceuticals Inc
14/07/202113:13Edgar (US Regulatory)Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)NASDAQ:ALXNAlexion Pharmaceuticals Inc
14/07/202106:11Dow Jones NewsAstraZeneca Says $39 Billion Alexion Deal Set for Completion After UK Clearance -- UpdateNASDAQ:ALXNAlexion Pharmaceuticals Inc
14/07/202103:30Dow Jones NewsUK Regulator Clears AstraZeneca's Alexion DealNASDAQ:ALXNAlexion Pharmaceuticals Inc
11/06/202104:01Business WireCaelum & Alexion Present Additional Phase 2 Data Reinforcing Safety & Tolerability of CAEL-101 in AL Amyloidosis at the Europ...NASDAQ:ALXNAlexion Pharmaceuticals Inc
07/06/202114:55Business Wire Alexion Announces FDA Approval of ULTOMIRIS® (ravulizumab-cwvz) for Children & Adolescents with Paroxysmal Nocturnal Hemog...NASDAQ:ALXNAlexion Pharmaceuticals Inc
04/06/202117:22Dow Jones NewsAstraZeneca Taps Alexion Executive for CFO Job -- UpdateNASDAQ:ALXNAlexion Pharmaceuticals Inc
04/06/202103:40Dow Jones NewsAstraZeneca Names Aradhana Sarin as Next CFONASDAQ:ALXNAlexion Pharmaceuticals Inc
27/05/202103:43Dow Jones NewsAstraZeneca Prices EUR800 Million Bond OfferingNASDAQ:ALXNAlexion Pharmaceuticals Inc
26/05/202103:43Dow Jones NewsAstraZeneca Prices $7 Billion Bond Offering to Partly Fund Alexion AcquisitionNASDAQ:ALXNAlexion Pharmaceuticals Inc
25/05/202103:41Dow Jones NewsUK Watchdog Starts Investigation Into AstraZeneca's Acquisition of AlexionNASDAQ:ALXNAlexion Pharmaceuticals Inc
13/05/202109:06Edgar (US Regulatory)Amended Current Report Filing (8-k/a)NASDAQ:ALXNAlexion Pharmaceuticals Inc
12/05/202117:14Business WireCaelum and Alexion Announce Upcoming CAEL-101 Data Presentations at the European Hematology Association Congress 2021NASDAQ:ALXNAlexion Pharmaceuticals Inc
12/05/202117:01Business WireAlexion Announces Upcoming Data Presentations at the 26th European Hematology Association Virtual CongressNASDAQ:ALXNAlexion Pharmaceuticals Inc
12/05/202105:52TipRanksAlexion Investors Approve Acquisition By AstraZenecaNASDAQ:ALXNAlexion Pharmaceuticals Inc
11/05/202117:31Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ALXNAlexion Pharmaceuticals Inc
11/05/202110:28Business WireAlexion Shareholders Approve Acquisition by AstraZenecaNASDAQ:ALXNAlexion Pharmaceuticals Inc
30/04/202109:27Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:ALXNAlexion Pharmaceuticals Inc
30/04/202109:00Business WireAlexion Reports First Quarter 2021 ResultsNASDAQ:ALXNAlexion Pharmaceuticals Inc
28/04/202118:00Business WireUPDATED Alexion to Report First Quarter 2021 Results on Friday, April 30, 2021NASDAQ:ALXNAlexion Pharmaceuticals Inc
20/04/202109:00Business WireAlexion to Report First Quarter 2021 Results on Monday, May 3, 2021NASDAQ:ALXNAlexion Pharmaceuticals Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:ALXN

Seu Histórico Recente

USOTC
RSHN
RushNet (PK)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados

BLACK FRIDAY

ADVFN

Celebrating 25 years Est 1999-2024

Economize até 50%* para TRADER PLUS

1 ano 30%, 2 anos 40% e *3 anos 50%

*Ao longo de 3 anos $ 1475.65 apenas $ 737.82